Literature DB >> 17627577

Increased OPG expression and impaired OPG/TRAIL ratio in the aorta of diabetic rats.

Mauro Vaccarezza1, Roberta Bortul, Roberto Fadda, Marina Zweyer.   

Abstract

Despite accumulating evidence showing that TNF-related apoptosis inducing ligand (TRAIL) plays a role in vascular biology and that its decoy receptor osteoprotegerin (OPG) is expressed in the vessel wall, modulation of these TNF and TNF-R family members in the early phases of diabetes mellitus has not been investigated. The expression of TRAIL and of OPG was examined both at the mRNA and protein levels in control and streptozotocin (SZT)-induced diabetic rats at early time points after the induction of diabetes mellitus. No differences in the steady-state mRNA levels of TRAIL were noticed by quantitative RT-PCR among the two groups of animals. On the other hand, diabetic rats showed a rapid and significant increase of the steady-state mRNA levels of OPG in the aortic wall of diabetic animals with respect to vehicle-treated (control) animals. These findings were confirmed at the protein level by analysing the amount of TRAIL and OPG proteins in aortic lysates by either Western blot or immunohistochemistry. Thus, an abnormal elevation of the OPG/TRAIL ratio in the vessel wall characterizes the early onset of diabetes mellitus and might represent a molecular mechanism involved in the vascular dysfunction characterizing diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17627577     DOI: 10.2174/157340607781024456

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  9 in total

1.  Correlation of increased plasma osteoprotegerin and cardiovascular risk factors in patients with adult growth hormone deficiency.

Authors:  Jiajia Xia; Linman Li; Wei Ren; Xiaoya Zheng; Chan Liu; Jinchao Li; Tingying Chen; Xiaofeng Li; Lingli Wang; Yumei Hu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 2.  Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily.

Authors:  Allan Flyvbjerg
Journal:  Nat Rev Endocrinol       Date:  2010-02       Impact factor: 43.330

3.  Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy.

Authors:  A Jorsal; L Tarnow; A Flyvbjerg; H-H Parving; P Rossing; L M Rasmussen
Journal:  Diabetologia       Date:  2008-08-22       Impact factor: 10.122

4.  Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetes.

Authors:  Daniel Gordin; Aino Soro-Paavonen; Merlin C Thomas; Valma Harjutsalo; Markku Saraheimo; Mette Bjerre; Carol Forsblom; Allan Flyvbjerg; Per-Henrik Groop
Journal:  Diabetes Care       Date:  2013-07       Impact factor: 19.112

Review 5.  Osteoprotegerin in Cardiometabolic Disorders.

Authors:  C Pérez de Ciriza; A Lawrie; N Varo
Journal:  Int J Endocrinol       Date:  2015-05-11       Impact factor: 3.257

6.  Dyslipidemia and Diabetes Increase the OPG/TRAIL Ratio in the Cardiovascular System.

Authors:  Barbara Toffoli; Bruno Fabris; Giacomo Bartelloni; Fleur Bossi; Stella Bernardi
Journal:  Mediators Inflamm       Date:  2016-12-14       Impact factor: 4.711

Review 7.  TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?

Authors:  Stella Bernardi; Rebecca Voltan; Erika Rimondi; Elisabetta Melloni; Daniela Milani; Carlo Cervellati; Donato Gemmati; Claudio Celeghini; Paola Secchiero; Giorgio Zauli; Veronica Tisato
Journal:  Clin Sci (Lond)       Date:  2019-05-16       Impact factor: 6.124

8.  Association between serum osteoprotegerin level and renal prognosis in nondialysis patients with chronic kidney disease in the Korean Cohort Study for Outcomes in Patients with Chronic Kidney Disease (the KNOW-CKD Study).

Authors:  Tae Ryom Oh; Chana Myeong; Su Hyun Song; Hong Sang Choi; Sang Heon Suh; Chang Seong Kim; Eun Hui Bae; Wookyung Chung; Kyu Hun Choi; Kook Hwan Oh; Seong Kwon Ma; Soo Wan Kim
Journal:  Kidney Res Clin Pract       Date:  2021-12-29

Review 9.  Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications.

Authors:  Mette Bjerre
Journal:  Springerplus       Date:  2013-12-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.